keyword
MENU ▼
Read by QxMD icon Read
search

Bimatoprost

keyword
https://www.readbyqxmd.com/read/28379653/factors-related-to-prostaglandin-associated-periorbitopathy-in-glaucoma-patients
#1
Chanikarn Patradul, Visanee Tantisevi, Anita Manassakorn
PURPOSE: To determine factors related to prostaglandin-associated periorbitopathy (PAP) and its prevalence in glaucoma or ocular hypertension (OHT) patients using prostaglandins analogs (PGAs). DESIGN: A cross-sectional study. METHODS: A study of glaucoma or OHT patients, using topical PGAs for at least 3 months, was performed. Eyes treated with PGAs were photoraphed and independently evaluated for PAP by 2 glaucoma specialists using at least 4 out of 7 clinical appearances...
March 29, 2017: Asia-Pacific Journal of Ophthalmology
https://www.readbyqxmd.com/read/28376651/evaluation-of-the-effects-on-choroidal-thickness-of-bimatoprost-0-03-versus-a-brinzolamide-1-0-timolol-maleate-0-5-fixed-combination
#2
Nurettin Akyol, Ahmet Kalkisim, Adem Turk, Mehmet Kola, Halil Ibrahim Imamoglu
OBJECTIVE: To investigate the effects of two different medical treatment options on choroidal thickness (CT) in cases of open-angle glaucoma (OAG). METHODS: 67 eyes newly diagnosed with OAG and 52 healthy eyes constituting the control group were included in the study. Glaucomatous eyes were randomly divided into two subgroups; Group I was started on bimatoprost 0.03% and Group II on a brinzolamide 1.0%/timolol maleate 0.5% fixed combination (BTFC). Intraocular pressure (IOP), ocular pulse amplitude (OPA), and subfoveal CT measurements were performed in all eyes in the study before treatment and on weeks 2, 4 and 8 after treatment...
April 4, 2017: Cutaneous and Ocular Toxicology
https://www.readbyqxmd.com/read/28369019/in-vivo-effects-of-retrobulbar-bimatoprost-injection-on-orbital-fat
#3
Kian Eftekhari, M Reza Vagefi, Vivian Lee, James Z Hui, Menglong Zhu, Kimberly Dine, Richard L Anderson, Brigitte Koeberlein, Reas Sulaimankutty, Kenneth S Shindler
PURPOSE: Recent publications have reported the adverse effects of prostaglandin analogues on the periocular tissues. These medications may cause periorbital lipodystrophy, enophthalmos, and deepening of the superior sulcus deformity. While these effects may have adverse consequences for some patients, the atrophy of the periorbital fat may have a useful role in diseases that lead to orbital and periorbital fat hypertrophy such as thyroid eye disease. In this pilot study, the authors investigated the effects of retrobulbar bimatoprost injection on the intraocular pressure and orbital fat in a rat animal model...
March 31, 2017: Ophthalmic Plastic and Reconstructive Surgery
https://www.readbyqxmd.com/read/28264599/bimatoprost-for-the-treatment-of-eyelash-eyebrow-and-scalp-alopecia
#4
REVIEW
Yevher Lorena Barrón-Hernández, Antonella Tosti
Alopecia is a common condition observed among people of all ages. It is a disorder that can involve only the scalp as observed in androgenetic alopecia or scalp and body as in alopecia areata or patients under chemotherapy treatment. There are several treatment options with different safety and efficacy outcomes. Bimatoprost, a synthetic prostamide F2α analog originally approved for the treatment of ocular hypertension and open-angle glaucoma, is now FDA approved as a 0.03%, solution to be applied once daily to increase eyelashes growth...
April 2017: Expert Opinion on Investigational Drugs
https://www.readbyqxmd.com/read/28217551/cost-effectiveness-of-glaucoma-management-with-monotherapy-medications-in-egypt
#5
Amal Abd-Elaal El-Khamery, Amir Ibrahim Mohamed, Hassan Eisa Hassan Swify, Alaa Ibrahim Mohamed
Glaucoma is a serious chronic ophthalmic disease since it causes irreversible visual disability if untreated can lead to blindness. Treatment options include medications (classified into five major classes of drugs which are muscarinic cholinergic agonists, alpha-2 adrenergic agonists, beta-1 adrenergic antagonists, prostaglandins [PGs], and carbonic anhydrase inhibitors); use of laser therapy or conventional surgery. Pharmacoeconomic analysis helps in choosing among this variety of treatments. There is a great need for such analysis in Egypt since undergoing of it in different countries or societies may produce different results...
January 2017: Journal of Advanced Pharmaceutical Technology & Research
https://www.readbyqxmd.com/read/28176172/evaluation-of-retinal-ganglion-cell-function-after-intraocular-pressure-reduction-measured-by-pattern-electroretinogram-in-patients-with-primary-open-angle-glaucoma
#6
Joanna Karaśkiewicz, Krzysztof Penkala, Maciej Mularczyk, Wojciech Lubiński
BACKGROUND: To evaluate retinal ganglion cell (RGC) function after intraocular pressure (IOP) reduction measured by pattern electroretinogram (PERG) in patients with newly diagnosed, non-treated preperimetric and early stages of primary open-angle glaucoma (POAG). METHODS: Twenty-four eyes from 24 patients with POAG: 11 eyes with preperimetric glaucoma and 13 eyes with early glaucoma received Ganfort (®) (bimatoprost + timolol) once a day for a period of 1 month...
April 2017: Documenta Ophthalmologica. Advances in Ophthalmology
https://www.readbyqxmd.com/read/28165835/assessment-of-the-anterior-chamber-flare-and-macular-thickness-in-patients-treated-with-topical-antiglaucomatous-drugs
#7
Fırat Selen, Oya Tekeli, Özge Yanık
PURPOSE: To determine the changes in the anterior chamber flare and central macular thickness (CMT) under topical antiglaucomatous therapy. METHODS: This study included 121 eyes of 73 patients and 36 eyes of 18 controls. Glaucoma patients were divided into 3 groups (timolol maleate, latanoprost, and bimatoprost). Control eyes did not receive any medications. Flare and CMT measurements were performed at baseline and follow-up visits (15th day, and 1st, 3rd, 6th, and 12th month)...
April 2017: Journal of Ocular Pharmacology and Therapeutics
https://www.readbyqxmd.com/read/28151873/bimatoprost-induced-late-onset-choroidal-detachment-after-trabeculectomy-a-case-report-and-review-of-the-literature
#8
Shunsuke Nakakura, Asuka Noguchi, Hitoshi Tabuchi, Yoshiaki Kiuchi
BACKGROUND: Choroidal detachment (CD) is often observed at an early period particularly after trabeculectomy and glaucoma drainage implant surgery. However, topical antiglaucoma eye drop-induced CD is a rare complication. Here, we report a case of topical bimatoprost-induced late-onset CD after trabeculectomy and review the literature. CASE REPORT: A 74-year-old man who suffered from primary open-angle glaucoma underwent his initial trabeculectomy with mitomycin-C in the right eye...
February 2017: Medicine (Baltimore)
https://www.readbyqxmd.com/read/28146132/a-novel-convergent-synthesis-of-the-potent-antiglaucoma-agent-tafluprost
#9
Małgorzata Krupa, Michał Chodyński, Anna Ostaszewska, Piotr Cmoch, Iwona Dams
Tafluprost (AFP-168, 5) is a unique 15-deoxy-15,15-difluoro-16-phenoxy prostaglandin F2α (PGF2α) analog used as an efficacious ocular hypotensive agent in the treatment of glaucoma and ocular hypertension, as monotherapy, or as adjunctive therapy to β-blockers. A novel convergent synthesis of 5 was developed employing Julia-Lythgoe olefination of the structurally advanced prostaglandin phenylsulfone 16, also successfully applied for manufacturing of pharmaceutical grade latanoprost (2), travoprost (3) and bimatoprost (4), with an aldehyde ω-chain synthon 17...
January 31, 2017: Molecules: a Journal of Synthetic Chemistry and Natural Product Chemistry
https://www.readbyqxmd.com/read/28122407/effects-of-latisse-bimatoprost-0-03-per-cent-topical-solution-on-the-ocular-surface
#10
Etty Bitton, Claudine Courey, Pamela Giancola, Vasile Diaconu, Jack Wise, Walter Wittich
PURPOSE: LATISSE is marketed for the treatment of hypotrichosis (loss of eyelashes), using a prostamide analogue and preserved with benzalkonium chloride, which is an effective preservative; however, it also causes irritation to the ocular surface. LATISSE is applied to the lid margin; however, with the blink, some solution may fall onto the ocular surface. The objective of this study was to assess the effects of LATISSE on the ocular surface over two months. METHODS: Non-dry eye participants interested in eyelash lengthening were invited to a prospective uncontrolled, open-label clinical study using LATISSE for two months...
January 25, 2017: Clinical & Experimental Optometry: Journal of the Australian Optometrical Association
https://www.readbyqxmd.com/read/28053501/fixed-combination-of-travoprost-and-timolol-maleate-reduces-intraocular-pressure-in-japanese-patients-with-primary-open-angle-glaucoma-or-ocular-hypertension-analysis-by-prostaglandin-analogue
#11
Tadashi Nakano, Shiro Mizoue, Nobuo Fuse, Aiko Iwase, Shun Matsumoto, Keiji Yoshikawa
BACKGROUND: We have shown a decrease in mean intraocular pressure (IOP) by switching to travoprost/timolol fixed combination (TTFC) in subjects receiving prostaglandin analogue (PGA) monotherapy and requiring additional medication in a previous report. For analyzing factors affecting IOP reduction, baseline IOP and preceding PGA were selected as statistically and clinically significant factors. In this report, we examine IOP-lowering effect and adverse drug reactions by preceding PGA...
2017: Clinical Ophthalmology
https://www.readbyqxmd.com/read/28012819/bimatoprost-sustained-release-implants-for-glaucoma-therapy-6-month-results-from-a-phase-i-ii-clinical-trial
#12
Richard A Lewis, William C Christie, Douglas G Day, E Randy Craven, Thomas Walters, Marina Bejanian, Susan S Lee, Margot L Goodkin, Jane Zhang, Scott M Whitcup, Michael R Robinson
PURPOSE: To evaluate the safety and intraocular pressure (IOP)-lowering effect of a biodegradable bimatoprost sustained-release implant (Bimatoprost SR). DESIGN: Phase I/II, prospective, 24-month, dose-ranging, paired-eye controlled clinical trial. METHODS: At baseline following washout, open-angle glaucoma patients (n=75) were administered Bimatoprost SR (6-μg, 10-μg, 15-μg, or 20-μg) intracamerally in the study eye; the fellow eye began topical bimatoprost 0...
December 21, 2016: American Journal of Ophthalmology
https://www.readbyqxmd.com/read/27994439/impact-of-prostaglandin-glaucoma-drops-on-platelet-activating-factor-action-an-in-vitro-study
#13
COMPARATIVE STUDY
Marilita M Moschos, Eirini Nitoda, Irini P Chatziralli, Georgios D Panos, Constantinos A Demopoulos
AIM: The aim of this study was to investigate the effect of different prostaglandin analogs on platelet-activating factor (PAF) levels. METHODS: Three prostaglandin analogs were selected: bimatoprost 0.3 mg/mL, latanoprost 50 μg/mL, and tafluprost 15 μg/mL. Each drug sample was tested for its ability to cause platelet aggregation, which was measured as PAF-induced aggregation, before and after the addition of various concentrations of the examined sample, creating a linear curve of percentage inhibition (ranging from 0% to 100%) versus different concentrations of the sample...
2016: Drug Design, Development and Therapy
https://www.readbyqxmd.com/read/27957367/bimatoprost-induced-serous-macular-detachment-after-cataract-surgery
#14
Swapnil Parchand, Subashini Kaliaperumal, Amit Kumar Deb, K Ramesh Babu, Renuka Srinivasan
We report a case of bimatoprost induced serous macular detachment and choroidal folds following uneventful cataract surgery. A 66-year-old male using topical bimatoprost in both eyes for open angle glaucoma underwent uneventful cataract surgery in the right eye. Postoperatively, he was restarted on topical bimatoprost and antibiotic-steroids combination drops. One week after surgery, he presented with conjunctival hyperemia, serous macular detachment, and choroidal folds at the posterior pole. Fundus fluorescein angiography showed perifoveal leaks in early stage with pooling of dye in late stage...
2016: Case Reports in Ophthalmological Medicine
https://www.readbyqxmd.com/read/27906815/structural-and-histologic-eyelid-changes-associated-with-6-months-of-topical-bimatoprost-in-the-rabbit
#15
Tiffany L Kent, Philip L Custer
PURPOSE: To determine the periorbital effects of daily 0.03% bimatoprost in New Zealand white (NZW) rabbits. MATERIALS AND METHODS: NZW rabbits were treated with daily 0.03% bimatoprost, artificial tears, or left untreated. Following 3 and 6 months of treatment, eyelid measurements were obtained for both upper and lower eyelid distraction, as well as canthus-to-canthus measurements. Once complete, subjects were humanely euthanized and eyelid tissue was utilized for histology...
March 2017: Journal of Glaucoma
https://www.readbyqxmd.com/read/27799736/efficacy-and-tolerability-of-benzalkonium-chloride-free-travoprost-in-glaucoma-patients-switched-from-benzalkonium-chloride-preserved-latanoprost-or-bimatoprost
#16
Julian García-Feijoo, Francisco J Muñoz-Negrete, Douglas A Hubatsch, Gemma C Rossi
INTRODUCTION: The preservative benzalkonium chloride (BAK) is used to preserve several topical, intraocular pressure (IOP)-lowering glaucoma medications but can cause tolerability concerns that may lead to decreased adherence to treatment and ultimately diminish the effectiveness of IOP control. The study aimed to determine the efficacy and tolerability of BAK-free travoprost preserved with polyquaternium-1 in glaucoma patients switched from BAK-preserved latanoprost or bimatoprost. METHODS: This 12-week, open-label study was conducted in Europe between December 2011 and February 2013...
2016: Clinical Ophthalmology
https://www.readbyqxmd.com/read/27770310/treating-alopecia-areata-current-practices-versus-new-directions
#17
REVIEW
Aditya K Gupta, Jessie Carviel, William Abramovits
Alopecia areata (AA) is non-scarring hair loss resulting from an autoimmune disorder. Severity varies from patchy hair loss that often spontaneously resolves to severe and chronic cases that can progress to total loss of scalp and body hair. Many treatments are available; however, the efficacy of these treatments has not been confirmed, especially in severe cases, and relapse rates are high. First-line treatment often includes corticosteroids such as intralesional or topical steroids for mild cases and systemic steroids or topical immunotherapy with diphenylcyclopropenone or squaric acid dibutylester in severe cases...
February 2017: American Journal of Clinical Dermatology
https://www.readbyqxmd.com/read/27764023/sustained-drug-delivery-for-glaucoma-current-data-and-future-trends
#18
REVIEW
Ahmad A Aref
PURPOSE OF REVIEW: Sustained drug delivery has been recognized as a need for patients with ocular hypertension or glaucomatous optic neuropathy. Several sustained drug delivery systems and devices are currently on the horizon. This review aims to summarize initial results with these platforms, as reported in the literature, and also provide insight into their possible role in the glaucoma treatment paradigm. RECENT FINDINGS: Sustained drug delivery systems currently on the horizon include the topical bimatoprost ocular insert, travoprost and latanoprost punctal plugs, latanoprost-eluting contact lenses, bimatoprost and travoprost intraocular implants, as well as several other therapies in earlier stages of development...
March 2017: Current Opinion in Ophthalmology
https://www.readbyqxmd.com/read/27703324/preservative-free-bimatoprost-0-03-timolol-0-5-fixed-combination-in-patients-with-glaucoma-in-clinical-practice
#19
Stefan Pfennigsdorf, Peter Eschstruth, Stefan Häsemeyer, Cord Feuerhake, Gerrett Brief, Ioana Grobeiu, Andrew Shirlaw
PURPOSE: The aim of this study was to evaluate the efficacy and tolerability of, and compliance to, preservative-free (PF), fixed-combination (FC) bimatoprost 0.03%/timolol 0.5% in patients with primary open-angle glaucoma or ocular hypertension in a clinical practice setting. PATIENTS AND METHODS: This open-label study observed patients switched to PF FC bimatoprost 0.03%/timolol 0.5% due to insufficient intraocular pressure (IOP) control on previous therapies...
2016: Clinical Ophthalmology
https://www.readbyqxmd.com/read/27672307/preservative-free-bimatoprost-0-03-in-patients-with-primary-open-angle-glaucoma-or-ocular-hypertension-in-clinical-practice
#20
Lutz E Pillunat, Peter Eschstruth, Stefan Häsemeyer, Ulrich Thelen, Christian Foja, Richard Leaback, Stefan Pfennigsdorf
BACKGROUND: Intraocular pressure (IOP)-lowering medications for primary open-angle glaucoma and ocular hypertension commonly contain preservatives that can cause ocular surface damage in many patients. The purpose of this study was to evaluate the efficacy and tolerability of, and compliance to, preservative-free (PF) bimatoprost 0.03% in patients with primary open-angle glaucoma or ocular hypertension (IOP ≥18 mmHg) in a clinical practice setting. METHODS: This open-label study observed patients who were switched to PF bimatoprost 0...
2016: Clinical Ophthalmology
keyword
keyword
27282
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"